Biohaven Pharmaceutical Holding Company Ltd.

135.99+0.6500+0.48%Vol 571.15K1Y Perf 115.77%
Sep 15th, 2021 16:00 DELAYED
BID135.00 ASK140.00
Open135.56 Previous Close135.34
Pre-Market- After-Market-
 - -%  - -
Target Price
132.40 
Analyst Rating
Strong Buy 1.25
Potential %
-2.64 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/100/-53 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/100/-53 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/100/-53 
Income Ranking
 —    -
Price Range Ratio 52W %
95.71 
Earnings Rating
Strong Buy
Market Cap8.89B 
Earnings Date
8th Nov 2021
Alpha0.03 Standard Deviation0.16
Beta1.03 

Today's Price Range

133.51137.50

52W Range

57.70139.50

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
3.97%
1 Month
18.01%
3 Months
46.26%
6 Months
79.34%
1 Year
115.77%
3 Years
269.74%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
BHVN135.990.65000.48
AAPL149.030.91000.61
GOOG2 904.1236.00001.26
MSFT304.825.03001.68
XOM56.421.84003.37
WFC46.640.59001.28
JNJ165.420.62000.38
FB373.92-2.6100-0.69
GE102.161.78001.77
JPM158.161.09000.69
ProfitabilityValueIndustryS&P 500US Markets
76.60
-402.00
-391.90
-
-
RevenueValueIndustryS&P 500US Markets
189.53M
2.90
-
-
Earnings HistoryEstimateReportedSurprise %
Q02 2021-2.77-3.23-16.61
Q01 2021-2.92-4.21-44.18
Q04 2020-2.89-3.62-25.26
Q03 2020-2.74-3.27-19.34
Q02 2020-2.78-2.558.27
Q01 2020-2.28-2.39-4.82
Q04 2019-1.96-2.85-45.41
Q03 2019-2.00-2.04-2.00
Earnings Per EndEstimateRevision %Trend
9/2021 QR-2.6512.25Positive
12/2021 QR-2.5115.20Positive
12/2021 FY-12.176.53Positive
12/2022 FY-7.398.43Positive
Next Report Date8th Nov 2021
Estimated EPS Next Report-2.65
Estimates Count5
EPS Growth Next 5 Years %-
Volume Overview
Volume571.15K
Shares Outstanding65.40M
Shares Float58.03M
Trades Count8.75K
Dollar Volume51.29M
Avg. Volume620.30K
Avg. Weekly Volume355.54K
Avg. Monthly Volume343.72K
Avg. Quarterly Volume615.02K

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) stock closed at 135.99 per share at the end of the most recent trading day (a 0.48% change compared to the prior day closing price) with a volume of 573.41K shares and market capitalization of 8.89B. Is a component of indices and it is traded on NYSE exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 647 people. Biohaven Pharmaceutical Holding Company Ltd. CEO is Vlad Coric.

The one-year performance of Biohaven Pharmaceutical Holding Company Ltd. stock is 115.77%, while year-to-date (YTD) performance is 58.66%. BHVN stock has a five-year performance of %. Its 52-week range is between 57.7 and 139.5, which gives BHVN stock a 52-week price range ratio of 95.71%

Biohaven Pharmaceutical Holding Company Ltd. currently has a PE ratio of -9.30, a price-to-book (PB) ratio of 29.80, a price-to-sale (PS) ratio of 45.61, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -137.37%, a ROC of -751.37% and a ROE of 361.70%. The company’s profit margin is -%, its EBITDA margin is -391.90%, and its revenue ttm is $189.53 Million , which makes it $2.90 revenue per share.

Of the last four earnings reports from Biohaven Pharmaceutical Holding Company Ltd., there were 0 positive earnings surprise and 4 negative earnings surprise. The company has EPS estimate of $-2.65 for the next earnings report. Biohaven Pharmaceutical Holding Company Ltd.’s next earnings report date is 08th Nov 2021.

The consensus rating of Wall Street analysts for Biohaven Pharmaceutical Holding Company Ltd. is Strong Buy (1.25), with a target price of $132.4, which is -2.64% compared to the current price. The earnings rating for Biohaven Pharmaceutical Holding Company Ltd. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Biohaven Pharmaceutical Holding Company Ltd. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Biohaven Pharmaceutical Holding Company Ltd. has a Buy technical analysis rating based on Technical Indicators (ADX : 5.97, ATR14 : 4.90, CCI20 : 76.35, Chaikin Money Flow : -0.02, MACD : 4.04, Money Flow Index : 71.44, ROC : 4.46, RSI : 61.41, STOCH (14,3) : 75.96, STOCH RSI : 1.00, UO : 37.53, Williams %R : -24.04), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Biohaven Pharmaceutical Holding Company Ltd. in the last 12-months were: Charles Conway (Option Excercise at a value of $0), Elyse Stock (Option Excercise at a value of $0), Gregory Hugh Bailey (Sold 50 000 shares of value $3 959 252 ), James Engelhart (Option Excercise at a value of $0), John Tilton (Option Excercise at a value of $0), John W. Childs (Buy at a value of $2 495 867), Kimberly Gentile (Option Excercise at a value of $218 315), Kimberly Gentile (Sold 23 500 shares of value $1 794 082 ), Vlad Coric (Option Excercise at a value of $0), William B.J. Jones (Option Excercise at a value of $1 521 600), William B.J. Jones (Sold 30 000 shares of value $2 286 676 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
7 (87.50 %)
7 (77.78 %)
7 (77.78 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (12.50 %)
2 (22.22 %)
2 (22.22 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.25
Strong Buy
1.44
Strong Buy
1.44

Biohaven Pharmaceutical Holding Company Ltd.

Biohaven Pharmaceutical Holding Co Ltd is a clinical-stage biopharmaceutical company. It has a portfolio of late-stage product candidates targeting neurological diseases, including rare disorders. The company product candidates are based on multiple mechanisms-calcitonin gene-related peptide receptor antagonists, glutamate modulators and myeloperoxidase inhibitor. Its pipeline products include BHV3000-301, BHV3000-302, BHV3000-303, and others.

CEO: Vlad Coric

Telephone: +1 203 404-0410

Address: C/o Biohaven Pharmaceuticals, Inc., New Haven 06510, CT, US

Number of employees: 647

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

83%17%

Bearish Bullish

59%41%

Bearish Bullish

68%32%

News

Stocktwits